T. Wasada et al., HYPERGLYCEMIA FACILITATES URINARY-EXCRETION OF C-PEPTIDE BY INCREASING GLOMERULAR-FILTRATION RATE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS, Metabolism, clinical and experimental, 44(9), 1995, pp. 1194-1198
We have evaluated the feasibility of monitoring the 24-hour urinary ex
cretion rate of C-peptide (U-CPR) as a measure of integrated beta-cell
function in patients with non-insulin-dependent diabetes mellitus (NI
DDM). In 37 normoalbuminuric patients, U-CPR of 117.9 +/- 9.1 mu g/d (
mean +/- SEM) during the poorly controlled glycemic phase (fasting pla
sma glucose [FPG], 171 +/- 7 mg/dL; hemoglobin A(1c) [HbA(1c)], 8.8% /- 0.4%) was significantly higher than the value of 83.3 +/- 13.7 mu g
/d (P < .001) during the well-controlled phase (FPG, 135 +/- 6 mg/dL;
HbA(1c) 7.0% +/- 0.2%), although the plasma insulin response to meals
was lower during the former phase (53.3 +/- 6.3 mu U/mL) versus the la
tter phase (65.7 +/- 6.6, P < .005). Endogenous creatinine clearance (
Ccr) was significantly elevated during the poorly controlled phase (10
5.4 +/- 7.3 v 88.7 +/- 4.7 mL/min, P < .005). In 26 microalbuminuric p
atients, the plasma insulin response was greater during good glycemic
control, but U-CPR did not differ between the two phases. Ccr was comp
arable at two phases in this group (92.7 +/- 7.4 v 91.1 +/- 5.9 mL/min
, NS). U-CPR correlated positively with Ccr in both groups (r = .593,
P < .001 in normoalbuminuria; r = .585, P < .001 in microalbuminuria).
In addition, when biosynthetic human C-peptide was infused intravenou
sly at an identical rate in two healthy subjects, resulting steady-sta
te plasma levels of CPR were lower, and fractional U-CPR was higher du
ring the moderately hyperglycemic phase versus the euglycemic phase. T
he calculated metabolic clearance rate (MCR) of C-peptide was found to
be increased in the presence of hyperglycemia. These results suggest
that hyperglycemia enhances U-CPR through an increase of glomerular fi
ltration rate (GFR), and therefore U-CPR as an index of residual beta-
cell function in diabetes should be used cautiously. Copyright (C) 199
5 by W.B. Saunders Company